Whenever ‘materials’, such as cell lines, anti-bodies, model systems (plants/animals), databases or other substances, are transferred from one institution or company to another, arrangements on the use of such materials should be covered in a material transfer agreement (MTA) .
The materials should only be used for the purpose the materials were released for. Furthermore, the materials are and continue to be the property of the party providing them. They may not be given to other parties without the consent of the providing party. As a general rule, the party providing the materials also provides a contract template to the second party.
MTA process for IXA VU and VUmc
To properly asses an MTA request, IXA requires you to fill out an intake form. This form contains all relevant information for the legal department to develop/review the agreement. If you have received an MTA from an external party, please include the draft MTA together with IXA’s intake form.
For non-biobank MTA’s, please download and fill in the appropriate intake form and send with the received MTA (if applicable) to IXA.
CimCure, a spin-off of Amsterdam UMC and focusing on cancer immunotherapies for solid tumors, signed a strategic partnership agreement for in-licensing CimCure’s iBoost technology with Intravacc, a worldwide leading translational research and development vaccine organization with an extensive track record in developing viral and bacterial vaccines. The iBoost (immune boost) technology was developed at Amsterdam […]News
MedTech startup Sirius Medical has received CE Mark approval for Sirius Pintuition, a non-radioactive device to localize breast tumors. In 2016 Bram Schermers, then a scientist at NKI, pitched an early concept at the annual Amsterdam Science & Innovation Awards and won first prize! His pitch also caught the attention of seasoned entrepreneur Hubert Martens, […]News
An annual survey held by the program directors of the Joint Master Entrepreneurship (UvA/ VU), Bram Kuijken and Enno Masurel, has found that 17.8% of alumni have founded their own company and 11.0% are currently working freelance. Additionally, the study found that 41.9% of alumni is employed by a startup (19.7%) or a scale-up (22.2%). […]News